Relmada Therapeutics, Inc. financial data

Symbol
RLMD on Nasdaq
Location
2222 Ponce De Leon Blvd. 3 Rd Floor, Coral Gables, FL
State of incorporation
NV
Fiscal year end
December 31
Former names
CAMP NINE, INC. (to 7/14/2014)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 732 % -41.3%
Return On Equity -78.5 %
Return On Assets -112 % -30.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.2M shares +0.25%
Common Stock, Shares, Outstanding 30.2M shares +0.25%
Entity Public Float 73M USD -87%
Common Stock, Value, Issued 30.2K USD +0.25%
Weighted Average Number of Shares Outstanding, Basic 30.2M shares +0.25%
Weighted Average Number of Shares Outstanding, Diluted 30.2M shares +0.25%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 49.9M USD -25.4%
General and Administrative Expense 41.7M USD -14.3%
Operating Income (Loss) -91.6M USD +20.7%
Nonoperating Income (Expense) 5.16M USD +28.8%
Net Income (Loss) Attributable to Parent -86.5M USD +22.5%
Earnings Per Share, Basic -2.87 USD/shares +22.4%
Earnings Per Share, Diluted -2.87 USD/shares +1.37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.48M USD -77.8%
Other Assets, Current 256K USD
Assets, Current 55.7M USD -48.9%
Other Assets, Noncurrent 22K USD -53.9%
Assets 55.7M USD -48.9%
Accounts Payable, Current 2.35M USD -17.9%
Accrued Liabilities, Current 5.74M USD +3.16%
Liabilities, Current 8.09M USD -3.98%
Liabilities 8.1M USD
Retained Earnings (Accumulated Deficit) -622M USD -16.1%
Stockholders' Equity Attributable to Parent 47.6M USD -52.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 166M USD +129%
Liabilities and Equity 55.7M USD -48.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13M USD +21%
Net Cash Provided by (Used in) Financing Activities 222K USD
Net Cash Provided by (Used in) Investing Activities 10.1M USD -74.9%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 30.2M shares +0.25%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.5M USD +4686%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.48M USD -77.8%
Deferred Tax Assets, Valuation Allowance 110M USD -5.38%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.01 pure
Preferred Stock, Shares Authorized 200M shares +5614%
Additional Paid in Capital 670M USD +5.25%
Share-based Payment Arrangement, Expense 8.3M USD -26.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%